schedule decreases the potential leukemogenic effect of this drug by reducing the cumulative exposure to cytotoxic treatment. Our study suggests that busulphan is a warranted treatment for elderly patients with ET.
A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia
Leukemia ( PTEN is a novel tumor suppressor gene, mapped to 10q23.3, which can dephosphorylate phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P). PtdIns(3,4,5)P mediates growth factorinduced activation of intracellular signaling, in particular through the serine-threonine kinase Akt. Although incidences of inactivation of PTEN in various solid tumors have been described, the role of PTEN in hematological malignancies is unclear. To date, few studies have investigated PTEN expression in primary acute lymphoblastic leukemia (ALL), and the expression of PTEN in acute myeloid leukemia (AML) remains controversial. 1, 2 We used quantitative flow cytometry to characterize the expression of PTEN in bone marrow from both healthy donors and acute leukemia patients, and applied the Kolmogorov-Smirnov (KS) statistical test to make analysis more straightforward. Staining intensity was evaluated by comparing binding of anti-PTEN antibody with that of isotype control, and the Kolmogorov-Smirnov test used to calculate a D-value, ranging from 0 to 1, to describe the difference.
Primary bone marrow samples were fixed and permeabilized with an Intraprep kit (cat. no. IM2389, Beckman Coulter, FL, USA) and then stained with anti-PTEN antibody (cat. no. sc-9145, Santa Cruz Biotechnology, CA, USA) according to the manufacturers' instructions. We first analyzed PTEN expression in five normal bone marrow samples. To compare the expression of PTEN in lymphocyte, granulocyte and monocyte fractions, we set the gates on forward scatter versus side scatter (FSC/SSC) plots to acquire 5000 cells of each population for analysis ( Figure 1a) . Lymphocytes, granulocytes and monocytes showed comparable levels of PTEN expression, with average D-values of 0.9370.05, 0.9770.02 and 0.9570.03, respectively (Figure 1b-d) .
We then analyzed the expression of PTEN in AML and ALL blasts. All the leukemia samples included in this study were freshly isolated to avoid the possibility of protein degradation during cycles of freeze-thaw. To identify the blast cells, we stained the leukemic bone marrow samples with CD45 PerCP before fixation. The blast cell population could be distinguished from other cells by the level of CD45 expression and the degree of side scatter. Blasts showed a lower level of CD45 expression than normal cells, and had intermediate side scatter (Figure 1e, g and i) . In the 26 patients with de novo AML (1 M0, 2 M1, 11 M2, 3 M3, 6 M4, 2 M5 and 1 M6) included in this study, we observed variable expression levels of PTEN (Figure 1o ). Generally, PTEN expression could be detected in all samples tested, although at a level significantly lower than that in normal cell populations ( Figure 1f Figure 1n ). However, this observation needs to be validated in more patients, and its implications should be further investigated. We could not establish whether PTEN expression level correlated with leukemia FAB subtype because of the limited number of patients in our study.
We next investigated PTEN expression in the blast cells of eight pediatric patients with B-cell ALL (B-ALL), and noted that in the vast majority of patients tested, B-ALL blasts expressed PTEN at a particularly low level, with a D-value of 0.5170.05 (Figure 1h ). Although few studies have addressed the question of PTEN expression in primary ALL patients, a recent study demonstrated that the PTEN promoter was methylated in 20% of ALL patients, 3 which may suggest that absent/low PTEN expression is a frequent event in ALL. Since T-cell ALL (T-ALL) is rare in China, we included only two cases of T-ALL in this study, both of which showed a slightly stronger expression of PTEN (D-value 0.74) than B-ALL blasts.
Two recent studies demonstrated that PTEN plays an essential role in prevention of leukemogenesis and hematopoietic stem cell exhaustion in mice. 4, 5 In the present study, we found that the level of expression of PTEN was low in the majority of B-ALL patients tested, a finding consistent with the report of frequent methylation of the PTEN promoter in ALL patients. 3 With regard to AML, we found, consistent with the some previous studies, 1, 2 that PTEN protein could be detected in all tested samples of primary AML blasts. However, our results showed that PTEN expression on AML blasts was generally lower than that on normal bone marrow cells. A possible reason for this discrepancy from the previous investigation is that the western blots are not sensitive enough to distinguish the degree of difference in PTEN expression revealed by our quantitative flow cytometry assay. Of note, the universal expression of PTEN in AML blasts did not exclude the possibility of an aberration in the PTEN/Skp2 signaling pathway, because PTEN phosphorylation status should also be taken into consideration. Such phosphorylation of PTEN can stabilize PTEN while making it unable to phosphorylate PtdIns(3,4,5)P. Recently, some studies reported PTEN phosphorylation in some AML patients and highlight the association of PTEN phosphorylation with poor prognosis. 2, 6, 7 In summary, our observation of low PTEN expression in acute leukemia suggests that this gene might play an important role in human acute leukemia. Previous studies have also suggested that PTEN can reverse MDM2-mediated resistance to chemotherapy in ALL cell lines. 8 However, in our patients, we did not find a significant correlation between the level of PTEN expression and the clinical response to the first course of induction chemotherapy. Long-term follow-up studies should be performed to investigate whether the level of PTEN expression in leukemic blasts is correlated with the risk of relapse and the overall duration of patient survival. 
. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; B-ALL, B-cell ALL; FSC/SSC, forward scatter versus side scatter; T-ALL, T-cell ALL.
More than 90% of patients with conventionally defined polycythemia vera (PV) are JAK2V617F-positive; the majority of the remaining carry other JAK2 exon 12 mutations. 1 On the basis of PCR sequencing of granulocyte-derived DNA from PV patients, we have previously reported an association between homozygous, as opposed to heterozygous, JAK2V617F mutation pattern and a higher hemoglobin level and increased frequency of pruritus. 2 These findings were recently confirmed by another study that used amplification-refractory mutation sequencing PCR assay 3 to measure JAK2V617F allele burden from granulocyte-derived mRNA in 116 patients with PV (Vannucchi AM et al. Blood 2006; 108: Abstract no. 5); in addition, mutant allele burden in this particular study (median 38%) directly correlated with leukocyte count, spleen size, thrombosis risk and need for treatment. In the current Institutional Review Board-approved study, 103 consecutive patients with PV were selected based on availability of both clinical and laboratory information at diagnosis and archived bone marrow, collected either at the time of diagnosis or during the chronic phase of the disease. All patients fulfilled World Health Organization diagnostic criteria for PV.
Previously published methodology was used for measuring JAK2V617F allele burden in bone marrow-derived DNA. 4 Quantitative PCR amplification and detection were performed on an ABI Prism 7900 HT Analyzer (Applied Biosystems, Foster City, CA, USA). Mutant allele burden was reported as the percentage of total JAK2 represented by JAK2V617F (that is JAK2V617F/JAK2V617F þ JAK2 wild type). 4 This JAK2V617F percentage was obtained from a standard curve for JAK2V617F/ total JAK2 against DC t (Ct JAK2V617F ÀCt JAK2WT ), which was constructed using various proportions of genomic DNA from the cell lines K562 (homozygous for wild-type JAK2) and HEL (homozygous for JAK2V617F). Two microliters of each standard mixture (25 ng/ml) and each sample (25 ng/ml) were aliquoted into separate wells of the 96 well plate. Standards and samples were run in triplicate and the mean DC t , for each standard mixture and sample was used to plot the JAK2V617F/JAK2 total percentage.
Overall, JAK2V617F was detected in 93 patients (90.3%); bone marrow-derived DNA for mutation analysis was collected within 1 year of diagnosis in 57 patients, 1 to 5 years of diagnosis in 20 patients and after 5 years of diagnosis in 16 patients. JAK2V617F allele burden was significantly higher in the latter group compared to the other two groups in whom test samples were collected within 5 years of diagnosis (Table 1 ; P ¼ 0.03). Such time-dependent increase in JAK2V617F allele burden in PV has previously been recognized whereas a similar phenomenon might not occur in essential thrombocythemia (ET); 5 for comparison, we have included, in Table 1 , bone marrow allele burden distributions over time from a previously published study in ET. 6 
Table 1
The effect of time of sample accrual on JAK2V617F allele burden in bone marrow-derived DNA from 93 and 96 mutation-positive patients with polycythemia vera (PV) or essential thrombocythemia (ET), respectively
Time of bone marrow sample collection JAK2V617F allele burden in mutation-positive PV cases (median and range) JAK2V617F allele burden in mutation-positive ET cases 6 (median and range)
At any time during chronic phase of the disease 16% (3-100%) (n ¼ 93) 6.3% (1-100%) (n ¼ 96) Within 1 year of diagnosis 15% (5-100%) (n ¼ 57) 6.5% (2.5-100%) (n ¼ 40) Between 1 and 5 years of diagnosis 14% (3-100%) (n ¼ 20) 5% (1-18%) (n ¼ 31) After 5 years of diagnosis 47% (8-100%) (n ¼ 16) 6.5% (2.5-15%) (n ¼ 25) P ¼ 0.03 P ¼ 0.62 JAK2V617F allele burden refers to the proportion of the mutant allele in relation to total JAK2 (that is, JAK2V617F/JAK2V617F + wild-type JAK2).
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